醫師介紹
醫師學術論文
Paper
學術機構典藏
論文
期刊論文
期刊論文/Journal Paper (作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄) |
日期 | |
1 | 山口浩史(Yamaguchi Hirohito)*、張玲菊(Ling-Chu Chang)、(Olin Shih-Shin Chang)、陳郁夫(Yu-Fu Chen)、蕭宇君(Yu-Chun Hsiao)、吳承修(Chen-Shiou Wu)、洪明奇(Mien-Chie Hung)*,MRCK as a Potential Target for Claudin-Low Subtype of Breast Cancer,International Journal of Biological Sciences,2024 Jan,20(1):1-14 | 2024 . 01 |
2 | 黃思澄(Sze-Ching Wong)、葉俊杰(Yeh, Chun-Chieh)、張勳瑜(Xun-Yu Zhang)、謝知穎(Chih-Ying Hsieh)、羅佳茜(CHIA-CHIEN, LO)、郭婷婷、林精湛(Ching-Chan Lin)、趙子華(Chih-Hua Chao)、劉璟霈(Liu, Jing-Pei)、張玲菊(Ling-Chu Chang)、王陸海(Lu-Hai Wang)、佘玉萍(Yuh-Pyng Sher)*,Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment,Molecular Oncology,2023 Apr,10.1002(): | 2023 . 04 |
3 | 謝清昀(Ching-Yun Hsieh)、林精湛(Ching-Chan Lin)、黃玉文(Yu-Wen Huang)、陳炯瀚(Jong-Hang Chen)、鄒永恩(Yung-An Tsou)、張玲菊(Ling-Chu Chang)、范紀鎮(Chi-Chen Fan)、林振源(Chen-Yuan,Lin)*、張為超(Wei-Chao Chang)*,Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling,JCI Insight,2022 Dec,7(23):e157285 | 2022 . 12 |
4 | 劉良智(Liang-Chih Liu)、沈宜君(Shen, Yi-Chun)、王元良(Yuan-Liang Wang)、鄔宛蓉、張玲菊(Ling-Chu Chang)、陳雅惠(Ya-Huey Chen)、李權峻(Chuan-Chun Lee)*、王紹椿(Shao-Chun Wang)*,Growth-promoting function of the cGAS-STING pathway in triple-negative breast cancer cells,Frontiers in Oncology,2022 Aug,12():851795 | 2022 . 08 |
5 | 張玲菊(Ling-Chu Chang)*、江世楷(Shih-Kai Chiang)、陳洵一(Shuen-Ei Chen)、洪明奇(Mien-Chie Hung)*,Targeting 2-oxoglutarate dehydrogenase for cancer treatment,American Journal of Cancer Research,2022 Apr,12(4):1436-1455 | 2022 . 04 |
6 | 江世楷(Shih-Kai Chiang)、陳洵一(Shuen-Ei Chen)、張玲菊(Ling-Chu Chang)*,The Role of HO-1 and Its Crosstalk with Oxidative Stress in Cancer Cell Survival,Cells,2021 Sep,10(9):2401 | 2021 . 09 |
7 | 邱宇任(YU?JEN CHIU)、蔡輔仁(Fuu-Jen Tsai)、包大靝(Da-Tian Bau)、張玲菊(Ling-Chu Chang)、謝閔凔(Min-Tsang Hsieh)、呂啟誠(CHI?CHENG LU)、郭盛助(Sheng-Chu kuo)*、楊家欣(Jai-Sing Yang)*,Next‑generation sequencing analysis reveals that MTH‑3, a novel curcuminoid derivative, suppresses the invasion of MDA‑MB‑231 triple‑negative breast adenocarcinoma cells,ONCOLOGY REPORTS,2021 Apr,46():133 | 2021 . 04 |
8 | 王元良(Yuan-Liang Wang)、張玲菊(Ling-Chu Chang)、陳坤堡(Kuen-Bao Chen)*、王紹椿(Shao-Chun Wang)*,Aptamer-guided targeting of the intracellular long-noncoding RNA HOTAIR,American Journal of Cancer Research,2021 Mar,11(3): | 2021 . 03 |
9 | (Yu-Feng Huang)、張玲菊(Ling-Chu Chang)、(Chung-Yu Chen)、(Yu-Hui Chen)、(Rosemary L. Walzem)、陳洵一(Shuen-Ei Chen)*,Unrestricted Feed Intake Induces b-cell Death and Impairs Insulin Secretion in Broiler Breeder Hens,Animals,2020 Oct,10(11):1969 | 2020 . 10 |
10 | (Jie-Ting Huang)、張玲菊(Ling-Chu Chang)、(Chung-Ssu Cheng)、(Jiang-Jen Lin)、(San-Yuan Huang)、(Shuen-Ei Chen)*,Cytotoxicity Produced by Silicate Nanoplatelets: Study of Cell Death Mechanisms,Toxins,2020 Sep,12():623 | 2020 . 09 |
11 | 范紀鎮(Chi-Chen Fan)、蔡昇達(Sheng-Ta Tsai)、林振源(Lin, Chen-Yuan)、張玲菊(Ling-Chu Chang)、楊顓丞(Juan-Cheng Yang)、陳冠宇(Guan-Yu Chen)、佘玉萍(Yuh-Pyng Sher)、王紹椿(Shao-Chun Wang)、蕭宏昇(Michael Hsiao)*、張為超(Wei-Chao Chang)*,EFHD2 Contributes to Non-Small Cell Lung Cancer Cisplatin Resistance by the Activation of NOX4-ROS-ABCC1 Axis,Redox Biology,2020 Jul,34():101571 | 2020 . 07 |
12 | (Shih-Kai Chiang)、張為超(Wei-Chao Chang)、(Shuen-Ei Chen)*、張玲菊(Ling-Chu Chang)*,DOCK1 regulates growth and motility through the RRP1B-Claudin-1 pathway in claudin-low breast cancer cells,Cancers,2019 Nov,11(11):1762 | 2019 . 11 |
13 | 劉良智(Liang-Chih Liu)、王元良(Yuan-Liang Wang)、(Pei-Le Lin)、(Xiang Zhang)、鄭維中(Cheng, Wei-Chung)、(Shu-Hsuan Liu)、陳芝蓉(Chih-Jung Chen)、(Yu Hung)、詹佳穎(Chia-Ing Jan)、張玲菊(Ling-Chu Chang)、(Xiaoyang Qi)、(Linda C. Hsieh-Wilson)、王紹椿(Shao-Chun Wang)*,Long non-coding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15,INTERNATIONAL JOURNAL OF CANCER,2019 Nov,145(9):2478-2487 | 2019 . 11 |
14 | 江世楷(Shih-Kai Chiang)、陳洵一(Shuen-Ei Chen)、張玲菊(Ling-Chu Chang)*,A dual role of heme oxygenase-1 in cancer Cells,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2019 ,20(1):39-56 | 2019 . |
15 | 張玲菊(Chang, Ling-Chu)*、(Shih-Kai Chiang)、(Shuen-Ei Chen)、余永倫(Yu, Yung-Luen)、鄒瑞煌(Chou, Ruey-Hwang)、張為超(Chang, Wei-Chao),Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis,CANCER LETTERS,2018 Jan,416():124-137 | 2018 . 01 |
16 | 張玲菊(Chang, Ling-Chu)、謝閔凔(Hsieh, Min-Tsang)、楊家欣(Yang Jai-Sing)、呂啟誠、蔡輔仁(Tsai, Fuu-Jen)、曹哲維、阮于寧(Yu-Ning Juan)、郭盛助(Kuo, Sheng-Chu)*、李國雄(Lee, Kuo-Hsiung)*,Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells,INTERNATIONAL JOURNAL OF ONCOLOGY,2017 Sep,(): | 2017 . 09 |
17 | 謝閔凔(Min-Tsang Hsieh)、張玲菊(Ling-Chu Chang)、洪欣儀(Hsin-Yi Hung)、林慧怡(Hui-Yi Lin)、施美卉(Mei-Hui Shih)、蔡長海(Chang-Hai Tsai)、郭盛助(Sheng-Chu Kuo)*、李國雄(Kuo-Hsiung Lee)*,New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo,EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2017 Mar,131():141-151 | 2017 . 03 |
18 | 張玲菊(Ling-Chu Chang)*、余永倫(Yung-Luen Yu)、謝閔凔(Min-Tsang Hsieh)、(Sheng-Hung Wang)、鄒瑞煌(Ruey-Hwang Chou)、黃偉謙(Wei-Chien Huang)、(Hui-Yi Lin)、(Hsin-Yi Hung)、郭盛助(Li-Jiau Huang),A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics,American Journal of Cancer Research,2016 Jun,6(4):747-763 | 2016 . 06 |
19 | 張玲菊(Ling-Chu Chang)、余永倫(Yung-Luen Yu)*,Dietary components as epigenetic-regulating agents against cancer,BioMedicine,2016 Mar,6(1):9-16 | 2016 . 03 |
20 | 張玲菊(Ling-Chu Chang)*、余永倫(Yung-Luen Yu)、(Chin-Yu Liu)、(Yung-Yi Cheng)、鄒瑞煌(Ruey-Hwang Chou)、謝閔凔(Min-Tsang Hsieh)、(Hui-Yi Lin)、(Hsin-Yi Hung)、黃麗嬌(Li-Jiau Huang)、吳永昌(Yang-Chang Wu)、郭盛助(Sheng-Chu Kuo)*,The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.,CANCER CHEMOTHERAPY AND PHARMACOLOGY,2015 Jun,75(6):1303-1315 | 2015 . 06 |
21 | (Mei-Juan Wang)、(Ying-Qian Liu)*、張玲菊(Ling-Chu Chang)、(Chih-Ya Wang)、(Yong-Long Zhao)、(Xiao-Bo Zhao)、(Keduo Qian)、(Xiang Nan)、(Liu Yang)、(Xiao-Ming Yang)、(Hsin-Yi Hung)、(Jai-Sing Yang)、(Daih-Huang Kuo)、(Masuo Goto)、(Susan L. Morris-Natschke)、(Shiow-Lin Pan)、(Che-Ming Teng)、(Sheng-Chu Kuo)、(Tian-Shung Wu)、吳永昌(Yang-Chang Wu)、李國雄(Kuo-Hsiung Lee)*,Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin as Potent Antitumor Agents,JOURNAL OF MEDICINAL CHEMISTRY,2014 ,57(**):6008-6018 | 2014 . |
研討會論文
研討會論文/Conference Papers (發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目) |
日期 | |
1 | The cGAS-STING pathway promotes the growth of triple-negative breast cancer cells by inhibiting autophagy,臺灣國際創新生物醫學峰會 2022 International Conference on Advanced Biomedical Sciences,中國醫藥大學水湳校區 卓越大樓 B2F國際會議廳,2022.11.04~2022.11.06, | 2022 . 11 |
2 | Growth-promoting function of the cGAS-STING pathway in triple-negative breast cancer cells,2021台灣國際創新生物醫學峰會,International Conference on Advanced Biomedical Sciences, Taiwan 2021 (ICABS, Taichung 2021),中國醫藥大學 水湳校區 卓越大樓B2F 國際會議廳,2021.11.19~2021.11.21, | 2021 . 11 |
3 | Heme oxygenase-1 mediates ferroptosis,AACR Annual Meeting,Chicago, Illinois, USA,2018.04.14~2018.04.18, | 2018 . 04 |
4 | New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo,第1屆臺灣藥學聯合學術研討會,國立成功大學醫學院,2018.01.13~2018.01.14, | 2018 . 01 |
5 | Roles of Tyrosine Phosphorylation of histone H4 in Breast Cancer,The 13th International Congress of Human Genetics (ICHG2016),Kyoto, Japan,2016.04.03~2016.04.07, | 2016 . 04 |
專書
暫無資料研究計畫
研究計畫/Research Grant (研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,計畫期間) |
日期 | |
1 | 個別型,MOST 110-2320-B-039-013-MY3,,科技部,GCN5調節鐵死亡之機制探討,2023.8.1~2024.7.31 | 2023 . 08 |
2 | 個別型,CBPTC-PROJ-2-2-2,,教育部,開發激活抗癌免疫力之抗體新療法 (B7-H3),2023.1.1~2023.12.31 | 2023 . 01 |
3 | 個別型,MOST 110-2320-B-039-013-MY3,,科技部,GCN5調節鐵死亡之機制探討,2022.8.1~2023.7.31 | 2022 . 08 |
4 | 個別型,CMU110-MF-03,,本校(含附醫),探討GCN5調節鐵死亡之機制與做為癌症治療之應用,2021.8.1~2022.7.31 | 2021 . 08 |
5 | 個別型,MOST 110-2320-B-039-013-MY3,,科技部,GCN5調節鐵死亡之機制探討,2021.8.1~2022.7.31 | 2021 . 08 |
6 | 個別型,CMU109-MF-68,,本校(含附醫),GCN5調控鐵死亡作用機制之探討,2020.9.8~2021.7.31 | 2020 . 09 |
7 | 個別型,DMR-110-011,,附醫院內計畫,探討KAT2A調控鐵死亡的作用機制興抗癌之應用,2020.8.1~2021.7.31 | 2020 . 08 |
8 | 個別型,MOST 109-2320-B-039-016,,科技部,GCN5促進鐵死亡機制之探討與在癌症治療的應用,2020.8.1~2021.7.31 | 2020 . 08 |
9 | 個別型,CMU108-MF-54,,本校(含附醫),Pyridazine 衍生化合物做為治療神經膠質細胞瘤藥物之研究,2019.9.9~2020.7.31 | 2019 . 09 |
10 | 個別型,DMR-109-131,,附醫院內計畫,探討DOCK1調控表基因修飾影響claudin低表達型三陰性乳癌生長與轉移之機制,2019.8.1~2020.7.31 | 2019 . 08 |
11 | 個別型,MOST 108-2320-B-039-040-,,科技部,小分子藥物pyridazine衍生化合物做為治療多形性神經膠質母細胞瘤藥物之開發與研究,2019.8.1~2020.7.31 | 2019 . 08 |
12 | 個別型,MOST 105-2628-B-039-004-MY3,,科技部,小分子藥物LDN/OSU-0212320系列化合物做為治療多形性神經膠質母細胞瘤藥物之開發與研究,2018.8.1~2019.7.31 | 2018 . 08 |
13 | 個別型,MOST 105-2628-B-039-004-MY3,,科技部,小分子藥物LDN/OSU-0212320系列化合物做為治療多形性神經膠質母細胞瘤藥物之開發與研究,2017.8.1~2018.7.31 | 2017 . 08 |
14 | 個別型,MOST 105-2628-B-039-004-MY3,,科技部,小分子藥物LDN/OSU-0212320系列化合物做為治療多形性神經膠質母細胞瘤藥物之開發與研究,2016.8.1~2017.7.31 | 2016 . 08 |
15 | 個別型,MOST 104-2314-B-039-034,,,低氧下SNAIL調節對乳癌腫瘤生長與轉移作用機制之探討,2015.8.1~2016.7.31 | 2015 . 08 |
16 | 個別型,DMR-104-107,郭盛助(Sheng-Chu Kuo)、張玲菊(Ling-Chu Chang),附醫院內計畫,合成含有新穎酯基官能基的薑黃素衍生物作為抗乳癌候選藥物,2015.2.1~2015.12.31 | 2015 . 02 |
17 | 個別型,DMR-104-108,,附醫院內計畫,薑黃素衍生物做為抗癌藥物之活性評估,2015.2.1~2015.12.31 | 2015 . 02 |
18 | 個別型,DMR-104-097,,附醫院內計畫,NF-kappaB調節的自噬作用在乳癌細乳生長角色之探討,2014.8.1~2015.6.30 | 2014 . 08 |
專利技術
專利/Patent (專利名稱,專利類別,專利國別,專利號碼,專利期間) |
日期 | |
1 | 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent,發明專利,韓國、韓國、韓國,KR 101844802,2018.3.28~2038.3.28 | 2018 . 03 |
2 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,加拿大,2,847,971,2017.10.24~2034.4.1 | 2017 . 10 |
3 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,中國大陸,ZL 2014 1 0133336.5,2017.9.1~2034.4.2 | 2017 . 09 |
4 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,歐盟,EP2786981,2017.8.16~2034.3.31 | 2017 . 08 |
5 | 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent,發明專利,美國、美國、美國,US9718835,2017.8.1~2037.8.1 | 2017 . 08 |
6 | Novel derivatives of curcuminoids and use thereof as an anticancer agent,發明專利,澳大利亞、澳大利亞、澳大利亞,2017286151,2017.6.2~2037.6.2 | 2017 . 06 |
7 | Derivatives of curcuminoids and use thereof as an anticancer agent,發明專利,美國,US10787413 B2,2017.6.2~2037.6.2 | 2017 . 06 |
8 | New derivatives of curcuminoids and their use as anticancer agents,發明專利,歐盟,KR102127852B1,2017.6.2~2037.6.2 | 2017 . 06 |
9 | DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICANCER AGENT,發明專利,加拿大,3020459,2017.6.2~2037.6.2 | 2017 . 06 |
10 | 新穎類薑黃素衍生物及其做為抗癌藥劑的用途,發明專利,台灣,I731096,2017.6.3~2037.6.2 | 2017 . 06 |
11 | A novel derivative of curcuminoid and its use as an anticancer agent,發明專利,日本,JP6940527B2,2017.6.2~2037.6.1 | 2017 . 06 |
12 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,台灣,I580670,2017.5.1~2034.3.27 | 2017 . 05 |
13 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,日本,特許6021847,2016.10.14~2034.4.1 | 2016 . 10 |
14 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,俄羅斯、俄羅斯、俄羅斯,25942581,2016.7.21~2034.3.28 | 2016 . 07 |
15 | 喜樹鹼的新穎20(S)-磺基脒衍生物及其抗腫瘤劑的用途,發明專利,台灣、台灣、台灣,TWI526446,2016.3.21~2034.9.18 | 2016 . 03 |
16 | 作為鱗狀癌及肝癌抑制劑的芪類化合物及其用途,發明專利,美國,US9,266,813,2016.2.23~2034.3.28 | 2016 . 02 |
17 | Stilbenoid Compounds As Inhibitors For Squamous Carcinoma And Hepatoma And Uses Thereof,發明專利,紐西蘭,623265,2014.4.1~2034.3.31 | 2014 . 04 |
18 | Stilbenoid Compounds As Inhibitors For Squamous Carcinoma And Hepatoma And Uses Thereof,發明專利,澳大利亞、澳大利亞、澳大利亞,61/807,837,2014.4.1~2034.4.1 | 2014 . 04 |
獲獎事蹟
暫無資料技術轉移
技術轉移/Technology Transfer (技術名稱,發明人,合約期間,專利名稱,授權單位,授權單位名稱) |
日期 | |
1 | 治療抗藥性非小細胞肺癌之小分子新藥,蔡長海(Chang-Hai Tsai)、郭盛助(Sheng-Chu kuo)、洪明奇(Mien-Chie Hung)、李國雄、謝閔凔(Min-Tsang Hsieh)、李培志(Lee, Pei-Chih)、林慧怡、張玲菊(Ling-Chu Chang)、莊聲宏(Juang, Shin-Hun)、楊家欣(Jai-Sing Yang)、洪欣儀(Hsin-Yi Hung),2023.2~2037.6,,本校(含附醫),朗齊生物醫學股份有限公司 | 2023 . 02 |